Dexamethasone Decreases the Delivery of Tumor-Specific Monoclonal Antibody to Both Intracerebral and Subcutaneous Tumor Xenografts
| Autor: | Edward A. Neuwelt, Fred L. Ramsey, Christopher I. McCormick, Karl Erik Hellström, Ingegerd Hellstrom, Peggy A. Barnett |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
medicine.medical_specialty
Chemotherapy biology medicine.drug_class business.industry medicine.medical_treatment Monoclonal antibody Blood–brain barrier Immunoglobulin G Endocrinology medicine.anatomical_structure Antigen Internal medicine biology.protein medicine Corticosteroid Surgery Neurology (clinical) Antibody business Dexamethasone medicine.drug |
| Zdroj: | Neurosurgery. 33:478-484 |
| ISSN: | 1524-4040 0148-396X |
| DOI: | 10.1097/00006123-199309000-00018 |
| Popis: | The effect of dexamethasone on the delivery of monoclonal antibody L6 IgG to intracerebral and subcutaneous LX-1 small cell lung carcinoma xenografts was evaluated in nude rats (n = 157). Dexamethasone (0, 8, or 24 mg/m2) was given 18 hours before infusion of L6 IgG, with or without osmotic disruption of the blood-brain barrier. Compared with controls, the 8 mg/m2 dose decreased delivery of L6 IgG (12-37%) to all tissues, but the only significant decrease (P 0.05). Compared with controls, the ratio of intracranial tumor to normal brain showed no change with dexamethasone, but the ratios of both intracranial and subcutaneous tumors to plasma significantly (P < 0.002) decreased with both doses. The in vitro cell binding capacity of L6 IgG to LX-1 cells remained unchanged after incubation of cells with dexamethasone over a 3-log concentration for 4 days, demonstrating no effect on antigen expression. This study suggests that dexamethasone has a clinically relevant generalized (i.e., central nervous system and systemic) vascular effect on permeability to L6 IgG monoclonal antibody. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|